FeesSafety
Pluang+

Telix reports 19% revenue growth in Q3 2026, FDA approves new brain cancer imaging drug Pixclara.

Company Fundamentals
21 Oct 2026, 01:10 WIB
GlobeNewsWire
View Source
Bullish
Telix reports 19% revenue growth in Q3 2026, FDA approves new brain cancer imaging drug Pixclara.

Telix Pharmaceuticals reported a 19% increase in group revenue to US$245 million for Q3 2026, driven by strong demand for its precision medicine products Gozellix and Illuccix. The FDA approved Pixclara for glioma imaging, marking a significant milestone with first commercial doses administered in September. Telix also announced a merger with Isotope Technologies Munich SE to expand its radiopharmaceutical platform and expects FY 2026 revenue to exceed US$1 billion. The company is advancing multiple clinical trials and expanding its manufacturing capabilities to support growth and innovation in cancer diagnostics and therapeutics.

Telix Pharmaceuticals' third quarter 2026 financial performance is presented here alongside Pluang's health sector market data for context. As of Oct 21, 2026 05:01 WIB, out of 150 priced health-sector US stocks on Pluang, 129 rose and 21 fell. Among notable movers, TDOC (Teladoc Health Inc) traded at USD 6.19 with a 1-day gain of 8.03% but showed a Pluang order activity heavily skewed to selling at 99%. In contrast, SYRE (Spyre Therapeutics Inc.) priced at USD 91.40 gained 7.88% with a balanced buy/sell order activity (53% buy). RVMD (Revolution Medicines Inc.) stood at USD 196.49, up 7.87%, with a typical hold time of 5 days on Pluang.

More News

Neuronetics grants inducement RSUs to a new employee under Nasdaq rules

Neuronetics grants inducement RSUs to a new employee under Nasdaq rules

Neuronetics, a leader in interventional mental health, awarded 9,000 restricted stock units (RSUs) to Julia Roussel as an inducement for employment, approved under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years, contingent on continue...

Company Fundamentals
Neutral
52 minutes ago
S&P 500 dips below 200-day average amid regulatory fears and hawkish Fed outlook

S&P 500 dips below 200-day average amid regulatory fears and hawkish Fed outlook

The S&P 500 fell 0.24%, slipping below its key 200-day moving average, driven by heavy losses in healthcare stocks due to new Medicare audit proposals. The Dow dropped 1.11%, while the Nasdaq rose 0.42% supported by tech and retail gains. The Federal...

Bearish
53 minutes ago
Cryptocurrency prices fall amid liquidity concerns and Fed policy uncertainty, Bitcoin nears $62,000 lows.

Cryptocurrency prices fall amid liquidity concerns and Fed policy uncertainty, Bitcoin nears $62,000 lows.

Cryptocurrency markets continued their decline on November 18, driven by worsening liquidity and cautious investor sentiment amid uncertainty about Federal Reserve policy. Bitcoin dropped nearly 4% to around $62,386, approaching recent lows, while Et...

Bearish
1 hour ago
Opendoor shares rise 7.63% on new FSBO.com deal and insider buying amid housing market challenges

Opendoor shares rise 7.63% on new FSBO.com deal and insider buying amid housing market challenges

Opendoor Technologies' stock rose 7.63% to $1.27 following a new partnership with FSBO.com and insider buying by a company director, signaling potential recovery. Despite a 12% sales increase to $1 billion in Q3, net losses widened to $218 million, r...

Market News
Bullish
1 hour ago
Invesco QQQ Trust dips 14% from record but could rise 36% by 2030 on earnings growth.

Invesco QQQ Trust dips 14% from record but could rise 36% by 2030 on earnings growth.

The Invesco QQQ Trust, tracking the Nasdaq-100, hit a record $759.66 in October but has since fallen about 14% to around $654. Despite this drop, it remains up 6% for 2026. The fund's future looks promising with an expected rise to $890 by 2030, driv...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App